Methylated CpG dinucleotides in the 5-α reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients

The inhibition of 5-α reductase type 2 (SRD5A2) by finasteride is commonly used for the management of urinary obstruction resulting from benign prostatic enlargement (BPE). Certain BPE patients showing no SRD5A2 protein expression are resistant to finasteride therapy. Our previous work showed that m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Zhe-Min, Fan, Dong-Dong, Jin, Song, Liu, Zhan-Liang, Niu, Yi-Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152415/
https://www.ncbi.nlm.nih.gov/pubmed/33243958
http://dx.doi.org/10.4103/aja.aja_63_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152415/
https://www.ncbi.nlm.nih.gov/pubmed/33243958
http://dx.doi.org/10.4103/aja.aja_63_20

Ejemplares similares